---
title: "Obefazimod (ABX464) in Ulcerative colitis: Sphingosine-1-phosphate receptor modulators"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: Sphingosine-1-phosphate receptor modulators. Topics: ACG 2025 guideline: recommendations for induction and maintenance; Mechanism and pivotal trial results: ACG 2025 evidence summary; ECCO 2026 guideline: recommendations and etrasimod safety; Ozanimod: indication, mechanism, dosing, and monitoring; 2 further topics. 6 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description/sphingosine-1-phosphate-receptor-modulators"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: Sphingosine-1-phosphate receptor modulators

<a id="heading-2.2.2.1.9"></a>

## 2.2.2.1.9 Sphingosine-1-phosphate Receptor Modulators

<a id="topic-2.2.2.1.9-1"></a>

### ACG 2025 guideline: recommendations for induction and maintenance

> “In patients with moderately to severely active UC, we recommend sphingosine-1-phosphate (S1P) receptor modulators, ozanimod and etrasimod, for induction of remission (Strong recommendation, moderate quality of evidence).”
> “We recommend continuing S1P receptor modulators ozanimod or etrasimod for maintenance of remission as compared wih no treatment after induction of remission with these agents (Strong recommendation, moderate quality of evidence).”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.9-2"></a>

### Mechanism and pivotal trial results: ACG 2025 evidence summary

> “The small molecule S1P receptor modulators ozanimod and etrasimod have a mechanism of action that sequesters activated lymphocytes in lymph nodes in patients with UC and results in decreased cellular inflammation in the bowel and a corresponding decreased circulating lymphocyte count.”
> “At the end of 10 weeks, a larger proportion of patients receiving ozanimod achieved clinical remission (18.4%) compared with placebo (6.0%, P < 0.001)).”
> “At the end of the maintenance period, 37% of patients continuing ozanimod achieved clinical remission compared with 18.5% of patients receiving placebo (P < 0.001).”
> “In the ELEVATE UC 52 study, at the completion of 12 and 52 weeks of treatment, 27% and 32% of patients receiving etrasimod achieved clinical remission compared with 7% and 7% of patients treated with placebo (P < 0.0001 for both comparisons).”
> “Unlike all other modern pivotal trials for moderately to severely active UC which excluded patients with isolated proctitis, the pivotal trials for etrasimod included patients with isolated proctitis and demonstrated a clinical remission rate in these patients of 43.2% at week 12, compared with 13.6% with placebo (P < 0.001).”
> “Significant cardiovascular disease, severe untreated sleep apnea, cardiac conduction defects, and concomitant use of monoamine oxidase inhibitors contraindicate the use of ozanimod.”

Source: [Rubin et al. (2025)](https://journals.lww.com/ajg/fulltext/10.14309/ajg.0000000000003463)

<a id="topic-2.2.2.1.9-3"></a>

### ECCO 2026 guideline: recommendations and etrasimod safety

> “We recommend treatment with ozanimod for the induction of remission in moderate-to-severe ulcerative colitis [strong recommendation, moderate certainty of evidence] [Agreement: 100%]”
> “We recommend treatment with etrasimod for the induction of remission in moderate-to-severe ulcerative colitis [strong recommendation, low certainty of evidence] [Agreement: 98%]”
> “There were isolated cases of bradyarrhythmias [mostly asymptomatic], occurring mainly during the initial days of treatment and resolving without specific intervention.”
> “In the etrasimod group, the incidence of macular edema was low and comparable with placebo. No increased infection risk or malignancies were reported in etrasimod trials.”

Source: [Gisbert et al. (2026)](https://academic.oup.com/ecco-jcc/article/20/7/jjag066/8726617)

<a id="topic-2.2.2.1.9-4"></a>

### Ozanimod: indication, mechanism, dosing, and monitoring

> “ZEPOSIA is a sphingosine 1-phosphate receptor modulator indicated for the treatment of:”
> “Moderately to severely active ulcerative colitis (UC) in adults.”
> “The recommended maintenance dosage is 0.92 mg orally once daily.”
> “Ozanimod blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood.”
> “Macular Edema: Increases the risk of macular edema. Obtain a baseline evaluation of the fundus, including the macula, near the start of treatment with ZEPOSIA.”

Source: [Zeposia prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209899s011s012lbl.pdf)

<a id="topic-2.2.2.1.9-5"></a>

### Etrasimod: indication, mechanism, and dosing

> “VELSIPITY is indicated for the treatment of moderately to severely active ulcerative colitis (UC) in adults.”
> “The recommended dosage is 2 mg orally once daily.”
> “Etrasimod partially and reversibly blocks the capacity of lymphocytes to egress from lymphoid organs, reducing the number of lymphocytes in peripheral blood.”

Source: [Velsipity prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/216956s002lbl.pdf)

<a id="topic-2.2.2.1.9-6"></a>

### Network meta-analyses: rankings of sphingosine-1-phosphate receptor modulators

> “After excluding JAK inhibitors as potential first-line treatment (in accordance with FDA), low-certainty evidence supports clinically important benefit with infliximab, ozanimod, risankizumab and guselkumab over adalimumab and mirikizumab for achieving remission with induction therapy in biologic-naïve patients with moderate-severe UC, with risankizumab and ozanimod being ranked the highest for induction of clinical remission.”

Source: [Ananthakrishnan et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12148344/)

> “In treat‐through studies, etrasimod 2 mg o.d. ranked first for clinical remission (RR = 0.73; 95% CI 0.64–0.83, p‐score 0.88)”

Source: [Barberio et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12151545/)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
